Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael E O'Dwyer

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Current Opinion in Oncology|December 20, 2002
Chronic myelogenous leukemiaMichael E O'Dwyer
Journal of the National Comprehensive Cancer Network : JNCCN|September 25, 2009
How to monitor patients with chronic myelogenous leukemiaMichael E O'Dwyer
Hematology/Oncology Clinics of North America|July 24, 2004
Clonal evolution in chronic myelogenous leukemiaJorge Cortes, Michael E O'Dwyer
Molecular Therapy. Oncology|May 7, 2026
Targeting intrinsic apoptosis rewires human NK cell persistence: NOXA as a dominant survival switchDavid Perea Pérez, Michael E O'Dwyer
Biologics : Targets & Therapy|April 27, 2017
New developments in the treatment of multiple myeloma - clinical utility of daratumumabCian McEllistrim, Janusz Krawczyk, Michael E O'Dwyer
Frontiers in Oncology|May 6, 2016
Targeting Selectins and Their Ligands in CancerAlessandro Natoni, Matthew S Macauley, Michael E O'Dwyer
Cancer Investigation|August 7, 2003
STI571 as a targeted therapy for CMLMichael E O'Dwyer, Michael J Mauro, Brian J Druker
Annual Review of Medicine|January 31, 2002
Recent advancements in the treatment of chronic myelogenous leukemiaMichael E O'Dwyer, Michael J Mauro, Brian J Druker
Experimental Hematology|July 24, 2002
In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemiaPaul La Rosée, Kara Johnson, Michael E O'Dwyer, et al.
Biomed Research International|October 29, 2015
Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and PrognosticsAlan Kirwan, Marta Utratna, Michael E O'Dwyer, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Current Opinion in Oncology|December 20, 2002
Chronic myelogenous leukemiaMichael E O'Dwyer
Journal of the National Comprehensive Cancer Network : JNCCN|September 25, 2009
How to monitor patients with chronic myelogenous leukemiaMichael E O'Dwyer
Hematology/Oncology Clinics of North America|July 24, 2004
Clonal evolution in chronic myelogenous leukemiaJorge Cortes, Michael E O'Dwyer
Molecular Therapy. Oncology|May 7, 2026
Targeting intrinsic apoptosis rewires human NK cell persistence: NOXA as a dominant survival switchDavid Perea Pérez, Michael E O'Dwyer
Biologics : Targets & Therapy|April 27, 2017
New developments in the treatment of multiple myeloma - clinical utility of daratumumabCian McEllistrim, Janusz Krawczyk, Michael E O'Dwyer
Frontiers in Oncology|May 6, 2016
Targeting Selectins and Their Ligands in CancerAlessandro Natoni, Matthew S Macauley, Michael E O'Dwyer
Cancer Investigation|August 7, 2003
STI571 as a targeted therapy for CMLMichael E O'Dwyer, Michael J Mauro, Brian J Druker
Annual Review of Medicine|January 31, 2002
Recent advancements in the treatment of chronic myelogenous leukemiaMichael E O'Dwyer, Michael J Mauro, Brian J Druker
Experimental Hematology|July 24, 2002
In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemiaPaul La Rosée, Kara Johnson, Michael E O'Dwyer, et al.
Biomed Research International|October 29, 2015
Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and PrognosticsAlan Kirwan, Marta Utratna, Michael E O'Dwyer, et al.
Pageof 3